This article is more than 5 years old. Information may no longer be current.

Sun Pharma to own Ocular Technologies plus rights to dry eye treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Sun Pharmaceutical Industries will acquire Ocular Technologies Sarta, or OTS, the owner of the rights to the dry eye disease treatment Seciera, according to a Sun Pharma press release.

Auven Therapeutics, which currently owns OTS, will receive a $40 million upfront payment from Sun Pharma, as well as “contingent developmental milestones and sales milestones,” and tiered royalties based on Seciera sales, the release said.

Ocular Technologies owns the worldwide rights to the ophthalmic solution Seciera (cyclosporine A 0.09%), which showed a “rapid onset of action” in a phase 2b/3 clinical trial in 455 patients and which is currently in phase 3 clinical trial, according to the release.

The U.S. Federal Trade Commission must approve the transaction, which is expected to be completed by the end of 2016.